The final rule requires the removal of
the pregnancy categories A, B, C, D, and X from all human
prescription drug and biological product labeling, and requires
that the labeling include a summary of the risks of using a drug
during pregnancy and lactation, a discussion of the data supporting
that summary, and relevant information to help health care
providers make prescribing decisions and counsel women about the
use of drugs during pregnancy and lactation. The final rule
eliminates the "Labor and delivery" subsection because information
about labor and delivery is included in the "Pregnancy" subsection.
The final rule requires that the labeling include relevant
information about pregnancy testing, contraception, and infertility
for health care providers prescribing for females and males of
reproductive potential.
US Code:
42
USC 262 Name of Law: Public Health Service Act
US Code: 21 USC 321(n) Name of Law: FD&C
Act
US Code: 21 USC 371(a) Name of Law: FD&C Act
US Code: 21 USC 502(f) Name of Law: FD&C Act
US Code: 42 USC 262 Name of Law: PHS Act
Ila Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.